Singapore
Curiox Biosystems is a biotechnology startup founded in 2008 and headquartered in Singapore. Dedicated to enabling accurate biological analysis through automation, the company's slogan, "Enabling accurate biological analysis through automation," reflects its core mission. Curiox has developed the innovative Laminar Wash technology, which eliminates centrifugation and its associated issues in preparing samples for next-generation biological analysis. This methodology preserves cells in their natural state, improving retention and viability, enhancing reproducibility and miniaturization, and ultimately reducing costs and standardizing workflows.
The company recently secured a notable $15.00M Series C investment on 16 March 2022, with KB Investments, QUAD Investment Management, and Luha Private Equity participating as key investors in this funding round. With this new investment, Curiox Biosystems is well-positioned to advance its automation technologies and expand its impact in the field of biological analysis, particularly in single-cell 'omics technologies, flow cytometry, immunotherapy, and cell and gene therapy applications.
